CMIP interacts with WT1 and targets it on the proteasome degradation pathway.

Shao-Yu ZhangQingfeng FanAnissa MoktefiVirginie OryVincent AudardAndre PawlakMario OlleroDjillali SahaliCarole Henique

Published in: Clinical and translational medicine (2022)

These data suggest that CMIP is a repressor of WT1 and might be a critical player in the pathophysiology of some podocyte diseases. Because WT1 is required for podocyte integrity, CMIP could be considered a therapeutic target in podocyte diseases.

Keyphrases

diabetic nephropathy
high glucose
endothelial cells
electronic health record
big data
artificial intelligence
data analysis